Abstract: As the central component of immune response, dendritic cells (DCs) are the most powerful antigen presenting cells. Compared with the conventional direct vaccination, ex vivo treatment of the DCs with tumor antigens generates more potent APC to stimulate antitumor response in vivo. This efficient cellular immuno-therapy is gaining increasing popularity in tumor vaccine preparation.